House Rx has secured $55 million in Series B equity and debt funding to expand its in-clinic specialty pharmacy model across more medical specialties and enhance its AI-driven pharmacy management system. The round was led by New Enterprise Associates (NEA) and Town Hall Ventures, with participation from LRVHealth, First Round Capital, Bessemer Venture Partners, and Silicon Valley Bank. This brings the company’s total funding to $100 million.
The San Francisco-based health technology company is reimagining specialty pharmacy by moving away from the Pharmacy Benefit Manager (PBM)-dominated, centralized model toward a decentralized network of locally owned, brick-and-mortar specialty dispensaries embedded directly within specialty clinics. This model aims to make specialty medications more accessible and affordable while improving patient outcomes through closer coordination between pharmacists and healthcare providers.
House Rx partners with specialty clinics to integrate pharmacy services into care delivery, enabling physicians to offer high-touch, localized alternatives that simplify administration and improve treatment outcomes for patients with complex conditions. The company currently collaborates with over 1,000 providers across 80 clinic sites nationwide. It processes about $1.5 billion in specialty prescriptions annually, a figure projected to double to $3 billion by the end of 2026.
The company’s proprietary pharmacy management system serves as the operational backbone of its medically integrated dispensaries, incorporating embedded AI workflows designed to streamline operations. Its recently launched “Smart PA” feature automates up to 80% of prior authorizations in pharmacy workflows. House Rx plans to introduce additional AI-native capabilities as part of its ongoing research and development investment.
KEY QUOTES:
“There’s finally momentum behind creating a specialty pharmacy system that makes it easier for patients to seamlessly and more affordably access the medications they desperately need. We’re seeing interest from stakeholders across the healthcare system — healthcare providers, manufacturers, payers, investors, and certainly employees who all recognize the opportunity to finally challenge the status quo in specialty pharmacy. We all want to do better by patients and help bring down the overwhelming expense to our healthcare system. With the support of this funding, we’re ready to scale operations to meet the exploding demand.”
Ogi Kavazovic, CEO & Founder, House Rx
“Specialty pharmacy is one of the highest-cost and least-transparent segments in healthcare and one that’s long overdue for change for the betterment of our healthcare system. NEA’s history of investing within specialty pharmacy and working with industry leaders in the category provides unique insight into its challenges, and we believe House Rx has an incredibly exciting vision to make a lasting change in this industry. The House Rx team is top notch, with a unique combination of specialty pharmacists and software builders working together to bring a new technology and service offering to market, making it cost effective for clinics to deliver complex specialty pharmacy services to their patients. We believe this model has the potential to change the landscape of specialty pharmacy for years to come.”
Blake Wu, Partner, New Enterprise Associates (NEA)
“The House Rx platform blends software with clinical services, so patients start life-saving treatments in days, not weeks. With the need for improved patient access and adherence to medications, solutions like House Rx have never been more urgent. We’re thrilled to support Ogi and his team of repeat healthcare and technology entrepreneurs in their mission to put providers and patients back in the center of the specialty pharmacy experience.”
David Whelan, Co-Founder and General Partner, Town Hall Ventures
